# US 2025/0320274 A1 · Recombinant human collagen and method for building same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0320274 A1
- Document ID: US20250320274A1
- Status: Published application
- Kind: A1
- Application number: 17/619,554
- Filed: 2020-06-09
- Published: 2025-10-16
- Earliest claimed: 2020-04-24
- Assignees: Nantong University
- Applicants: Nantong University
- Inventors: Xiaosong GU; Tianmei QIAN; Hongkui WANG; Hualin SUN; Yun GU
- Web page: https://patentgrep.com/patent/US20250320274A1

## CPC

- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- G16B 15/30: Drug targeting using structural data; Docking or binding prediction
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A recombinant human collagen and a method for building same are provided. The amino acid sequence of the recombinant human collagen is SEQ ID NO. 1: GPAGARGNDGATGAAGPPGPTGPAGPPGFP. The recombinant human collagen does not have a signal peptide and a transmembrane domain and is a novel hydrophilic protein. In addition, the protein does not have an antigenic determinant and does not elicit an immunological rejection response when applied to human body. The present invention further discloses a method for building and synthesizing a low-immunogenic hydrophilic recombinant human collagen. The recombinant human collagen synthesized by using the present invention has high purity, no virus risk, and a high expression level. The protein can be widely applied to related biomedical products, regenerative medicine products, tissue engineering and beauty products, health care products, cosmetic products, among others.

## Claims

### Claim 1

A recombinant human collagen, wherein,
an amino acid sequence of the recombinant human collagen is SEQ ID NO. 1:
GPAGARGNDGATGAAGPPGPTGPAGPPGFP.

### Claim 2 (depends on 1)

The recombinant human collagen according to claim 1, wherein,
the recombinant human collagen has a single-chain single-helix structure, presents a sequence feature of a collagen “Gly-X-Y”, X and Y being any amino acids other than glycine, has a full length of 30 amino acids, and is a human collagen type I peptide segment.

### Claim 3 (depends on 1)

The recombinant human collagen according to claim 1, wherein,
the recombinant human collagen has a molecular mass of 2526.71 Da and a theoretical isoelectric point of 5.84.

### Claim 4 (depends on 1)

The recombinant human collagen according to claim 1, wherein,
the recombinant human collagen does not have a signal peptide and a transmembrane domain and is a hydrophilic protein.

### Claim 5 (depends on 1)

The recombinant human collagen according to claim 1, wherein,
the recombinant human collagen is free of an antigenic determinant and is a low-immunogenic protein.

### Claim 6 (depends on 1)

The recombinant human collagen according to claim 1, wherein,
the recombinant human collagen is capable of forming a random coil structure.

### Claim 7 (depends on 1)

A method for building a recombinant human collagen according to claim 1, comprising the steps of,
step (1): acquiring a sequence of a human collagen type I from an NCBI database;
step (2): analyzing an antigenic determinant of the human collagen type I by using an online epitope prediction tool Predicted Antigenic Peptides, and performing screening to select a low antigenic determinant region; and
step (3): selecting a low antigenic determinant, hydrophilic region from the selected low antigenic determinant region by using BitGene online antigenic determinant prediction and in combination with five algorithms that are hydrophilicity, flexibility, surface accessibility, antigenicity and p turn prediction, and determining an amino acid sequence of a recombinant human collagen that needs to be synthesized, in combination with a sequence feature of the collagen.

### Claim 8 (depends on 7)

The method for building a recombinant human collagen according to claim 7, wherein,
the human collagen type I has a sequence number of NP_000079.2 and has a length of 1464 amino acids.

### Claim 9 (depends on 8)

The method for building a recombinant human collagen according to claim 8, wherein,
in step (2), the selected low antigenic determinant region is 171 amino acids at a position 230 to a position 400 in the human collagen type I.

### Claim 10 (depends on 9)

The method for building a recombinant human collagen according to claim 9, wherein,
in step (2), a low antigenic determinant region of 171 amino acids is analyzed by using five standard methods of epitope prediction that are BitGene online antigenicity, hydrophilicity, flexibility, surface accessibility and p turn, to determine an antigenic determinant of the low antigenic determinant region; and
a low antigenic determinant, high hydrophilicity region is selected, and the amino acid sequence of the recombinant human-derived collagen that needs to be synthesized is determined in combination with the sequence feature of the collagen, that is, a presented arrangement pattern “Gly-X-Y, X and Y being any amino acids other than glycine”.
